Skip to Content

CureVac NV Ordinary Shares CVAC Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CVAC

Currency in USD

Economic Moat


Capital Allocation


CureVac Focuses on Expanding Pipeline Through Enhanced Oncology Strategy; Maintaining $15.40 FVE

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

CureVac was founded in 2000, and its focus is on developing vaccines and therapies using messenger ribonucleic acid, or mRNA. mRNA offers several advantages, including cell-free, rapid, large-scale manufacturing and the ability to substitute new genetic sequences to create novel vaccines. Vaccines are typically composed of weakened viruses or proteins (antigens) that they express. In mRNA vaccines, the genetic code for an antigen is administered to patients who then manufacture the antigen themselves, which triggers an immune response.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CVAC

Company Profile CVAC

Business Description

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Friedrich-Miescher-Strasse 15
Tubingen, BW, 72076, Germany
T +49 707198830
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 1,000